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Translational Relevance 
Inhibition of the mTOR complex 1 (mTORC1) is important in the treatment of a diverse and 
growing range of tumours. However, in most cases the tumours concerned are highly 
heterogeneous at a molecular genetic level and tumour responses are unpredictable. By contrast, 
renal angiomyolipomas that develop in patients with the inherited disorder tuberous sclerosis and 
the related sporadic disorder lymphangioleiomyomatosis are specifically associated with 
inactivation of the TSC1 or TSC2 tumour suppressor genes that are key regulators of mTORC1. 
In this phase II trial 16 patients with these disorders and renal angiomyolipomas were treated for 
2 years with the mTORC1 inhibitor sirolimus. Angiomyolipoma burden was reduced in all 
patients and a response by RECIST criteria was observed in 50% overall and in 80% of the per 
protocol group. Our results suggest that mTORC1 inhibition may be an effective strategy for 
treating angiomyolipoma in these rare disorders and merits further study. 
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Abstract 
PURPOSE 
Renal angiomyolipomas are a frequent manifestation of tuberous sclerosis and sporadic 
lymphangioleiomyomatosis. These disorders are associated with mutations of TSC1 or TSC2 
that lead to over-activation of mammalian target of rapamycin complex 1 (mTORC1), 
suggesting an opportunity for targeted therapy using mTORC1 inhibitors. This study 
investigated the efficacy and safety of the mTORC1 inhibitor sirolimus for treatment of renal 
angiomyolipomas in patients with these disorders. 
 
EXPERIMENTAL DESIGN 
In this multicenter phase 2 non-randomized open label trial sixteen patients with tuberous 
sclerosis or sporadic lymphangioleiomyomatosis and renal angiomyolipoma(s) were treated 
with oral sirolimus for up to 2 years. Steady state blood levels were 3-10ng/ml. The primary 
outcome was change in size of renal angiomyolipomas measured by magnetic resonance 
imaging and assessed by RECIST criteria. Secondary outcomes included safety, 
neurocognitive function and pulmonary function. 
 
RESULTS 
The response rate, by RECIST criteria, was 50%. Summated angiomyolipoma diameters were 
reduced in all 16 patients and by 30% or more in 8 (all from the per-protocol group of 10). 
Forty one of 48 angiomyolipomas were smaller at the last measurement than at baseline. Most 
shrinkage occurred during the first year of treatment. There was little change in pulmonary 
function. Recall memory improved in 7 of 8 patients with tuberous sclerosis. Adverse events 
were consistent with the known toxicities of sirolimus. 
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CONCLUSIONS 
This study demonstrated sustained regression of renal angiomyolipomas in patients with 
tuberous sclerosis or sporadic lymphangioleiomyomatosis receiving 2 years of sirolimus 
treatment. Possible effects on pulmonary function and neurocognition require further 
investigation. 
 
 
TRIAL REGISTRATION 
clinicaltrials.gov identifier: NCT00490789 
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Introduction 
 
Tuberous sclerosis is an autosomal dominant disorder caused by mutations in either 
TSC1 or TSC2.1 It is characterised by development of tumours in many organs, including the 
kidneys and brain and by a range of neuropsychiatric manifestations that include seizures, 
cognitive impairments and autism.1 Renal angiomyolipomas affect up to 80% of patients 
causing morbidity and mortality due to haemorrhage and renal insufficiency. They do not 
regress spontaneously and current treatments include embolization and nephrectomy.2,3 
Lymphangioleiomyomatosis (LAM) is the main pulmonary manifestation and occurs almost 
exclusively in females. It can lead to respiratory failure as a consequence of proliferation of 
smooth-muscle-like cells (LAM cells) and cystic degeneration and may require lung 
transplantation.4,5 Lymphangioleiomyomatosis also occurs as a rare sporadic disorder 
associated with acquired mutations of TSC2 in women without tuberous sclerosis, forty percent 
of whom also have renal angiomyolipomas. Identical TSC2 mutations have been identified in 
their angiomyolipomas and pulmonary LAM cells indicating a clonal origin and a metastasis-
like disease process.6 The neuropsychiatric manifestations of tuberous sclerosis are ranked by 
families and carers among the most significant problems.7 Forty to 50% of patients have 
intellectual disability, but even those with normal intellectual abilities may have specific 
neurocognitive problems, including deficits in executive function and memory.8,9 
Mutation of TSC1 or TSC2 leads to over-activation of signaling via the mammalian 
target of rapamycin complex 1 (mTORC1), a regulator of cell growth.10 Angiomyolipomas 
exhibit biallelic TSC1 or TSC2 mutation and mTORC1 pathway activation2. In the central 
nervous system mTORC1 regulates neuronal differentiation, synaptic plasticity and the 
encoding of spatial and auditory memory.11,12 Sirolimus (rapamycin), a potent mTORC1 
inhibitor, reversed renal tumour growth, abnormal synaptic plasticity and deficits in spatial 
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recall memory in rodent models of tuberous sclerosis.13-15. Clinical studies indicate that 
sirolimus also reduces the size of kidney and brain tumours in patients with tuberous 
sclerosis.16-18 In a phase 1-2 trial in twenty patients with tuberous sclerosis or sporadic 
lymphangioleiomyomatosis, renal angiomyolipoma volumes were reduced by approximately 
50% after 12 months of sirolimus treatment but the tumours increased in size when treatment 
was stopped.19 In an interim report of the current trial we also showed size reduction of 
angiomyolipomas in patients who had been treated for up to 12 months.20 We have now 
evaluated the longer term efficacy and safety of sirolimus treatment for angiomyolipoma in 
adults with tuberous sclerosis or sporadic LAM. We also monitored aspects of neurocognitive 
function and, in those with LAM, assessed changes in lung function. 
 
Methods 
Eligibility 
Patients with a definite diagnosis of tuberous sclerosis21 or sporadic 
lymphangioleiomyomatosis22 were eligible if they were aged 18 to 65 years, had at least one 
renal angiomyolipoma of 2 cm or more in longest diameter and an estimated glomerular filtration 
rate (GFR)23 of at least 40 milliliters per minute. The major exclusion criteria were: 
angiomyolipoma embolization within 6 months or bleeding within 12 months, urinary protein 
excretion of  >1 gram per day, inability to walk 100 metres on the flat, requirement for 
continuous supplemental oxygen or an intelligence quotient (IQ) <70.  
 
Trial Design 
This trial was a prospective multicenter phase 2 study (ClinicalTrials.gov number, 
NCT00490789) conducted at the University Hospital of Wales (UK), Nottingham City Hospital 
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(UK), Royal Sussex Hospital (UK) and University Hospital Zürich (Switzerland) from October 
2005 through September 2009 in accordance with the United Kingdom Medicines for Human 
Use Regulations 2004, the Declaration of Helsinki, the Good Clinical Practice guidelines of the 
International Conference of Harmonization and local regulatory requirements. The Thames 
Valley Multi-Centre Research Ethics Committee approved the protocol and all patients gave 
written informed consent.  
 
Data Collection 
At baseline, angiomyolipomas were visualised by abdominal magnetic resonance imaging 
(MRI) without contrast media and measured. Up to five angiomyolipomas with longest 
diameters of 2.0cm or more were selected in each kidney as target lesions and their longest 
diameters were summated for each patient. Angiomyolipomas with a longest diameter of <2.0cm 
were recorded as non-target lesions. Oral liquid sirolimus was initiated at a daily dose of 0.5 
milligram per m2 body-surface-area and the dosage was adjusted to achieve steady-state levels 
between 3 and 6 ng/ml. Follow-up visits were at 3 weeks and at 2, 4, 6, 9, 12, 18 and 24 months 
after initiation and abdominal MRI was repeated at 2,6,12 and 24 months. If the longest diameter 
of all target lesions was not reduced by at least 10% at 2 months, the sirolimus dose was 
increased to achieve a steady-state level of 6 to 10 ng/ml.  
 
At each visit, blood creatinine, lipids, liver enzymes and hematologic parameters were 
measured, and protein and creatinine were measured in spot urine. GFR was estimated with the 
MDRD equation23. Steady-state levels of sirolimus were determined by liquid chromatography–
mass spectrometry from whole blood. Adverse events were classified according to the National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.  
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Imaging 
Transaxial unenhanced abdominal MRI scans were performed with 1.5 Tesla systems. 
Scans were acquired with T1-weighted fast spoiled gradient echo and T2-weighted fast spin 
echo protocols and reviewed by a single radiologist (TD). Cranial MRI was undertaken at 
baseline and, in patients with tuberous sclerosis, at 12 months using 1.5 Tesla systems. Axial 
T2 weighted images, axial FLAIR images and coronal 3D SPGR were obtained and reviewed 
by a single neuroradiologist (JJC). Computed tomography (CT) of the lungs was performed at 
baseline and at 24 months in patients with lymphangioleiomyomatosis. Images were obtained 
during full inspiration using a low dose protocol and reviewed by a single radiologist (KP). 
 
Pulmonary Function Testing 
 Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and 
diffusing capacity of the lung for carbon monoxide (DLco) were measured at baseline and at 4, 
6, 12 and 24 months in a lung function laboratory in all patients with 
lymphangioleiomyomatosis and expressed as percentage of predicted values24 to allow for 
change over time. 
 
Neurocognitive testing 
Neurcognitive tests were undertaken at baseline, 4 and 12 months in patients with 
English as their first language. IQ was determined for eligibility using the National Adult 
Reading Test.25 Recall Memory was tested using the List Learning, Story and Complex Figure 
tests from the Adult Memory and Information Processing Battery (AMIPB)26; Recognition 
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Memory using the Spatial Recognition Memory and Pattern Recognition Memory subtests 
from the Cambridge Neuropsychological Test Automated Batteries (CANTAB)27 and 
Executive Skills using the self-ordered Spatial Working Memory task (SWM), the Stockings of 
Cambridge (SoC) planning task and the Intra-Dimensional Extra-Dimensional (IDED) set-
shifting task, from CANTAB.27 
 
Statistical Analysis 
 The primary outcome was the number of patients in whom renal angiomyolipomas 
responded to sirolimus therapy. Response was evaluated by the Response Evaluation Criteria 
in Solid Tumors (RECIST)28 that define a “complete response” as the disappearance of all 
lesions,  a “partial response” as decrease of at least 30% in the sum of the longest diameters of 
target lesions without progression of non-target lesions, “progressive disease” as a 20% 
increase in the sum of the longest diameters of target lesions compared with the smallest value 
recorded since treatment started or progression of non-target lesions or appearance of 1 or more 
new lesions and “stable disease” as neither response nor progression. In this trial a response 
was defined as a complete or partial response that occurred at any time during the trial. 
 
 We aimed initially to recruit 15 patients with sporadic lymphangioleiomyomatosis and 
15 with tuberous sclerosis but because of slow recruitment we modified our plan to recruiting 
at least 14 patients in total. The minimum sample size of 14 was based on Fleming’s single 
stage design.29 p1 (the response rate below which the treatment would not be studied further) 
was set at 0.1 and p2 (the response rate above which the treatment would be studied further) at 
0.4. We set α (the probability of concluding that the response rate is greater than p1 when that 
is false) at 0.05 and β (the probability of concluding that the response rate is less than p2 when 
that is false) at 0.1. The primary analysis was based upon all patients. 
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The per protocol population included all patients in the study apart from those who 
received less than four months treatment at the higher sirolimus blood level of 6-10ng/ml, unless 
a response had been achieved.  
 
Annual rate of change in FEV1, FVC and DLco was determined by linear regression. 
For neurocognitive outcomes, we used published UK percentile bands for age and sex for 
each test to derive summary scores30 for each neurocognitive domain i.e. recall memory, 
recognition memory and executive function. 
 
Results 
Patients and Protocol Completion 
 Sixteen patients, 13 female and 3 male, were enrolled. Ten had tuberous sclerosis 
(including 3 with LAM) and 6 had sporadic lymphangioleiomyomatosis with no skin signs of 
tuberous sclerosis or manifestations of tuberous sclerosis on brain MRI scan. Four had 
undergone previous unilateral nephrectomy. Among the 12 patients with two kidneys the target 
angiomyolipomas (i.e. those of 2 cm or more in longest diameter) were bilateral in 6. During 
the trial one patient with severe sporadic lymphangioleiomyomatosis died from a respiratory 
infection, one withdrew for lung transplantation, one for elective surgery for angiomyolipoma, 
two because of protocol deviations and one because of likely sirolimus-related peripheral 
edema. Ten patients completed the 24 month trial (Figure 1). At 2 months, 4 patients were dose 
escalated to steady-state blood levels of 6-10 ng/ml. Others were maintained at 3-6 ng/ml 
without further dose escalation. 
 
Response of angiomyolipomas 
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 The overall response rate by the RECIST criteria28 was 50% (8 of 16) and in the per 
protocol group it was 80% (8 of 10). All were partial responses. They occurred in 4 of 10 
patients with tuberous sclerosis and 4 of 6 with sporadic lymphangioleiomyomatosis. At 24 
months a partial response was present in 4 of 10 patients (40%) remaining in the trial. 
Moreover, in every patient the sum of the longest diameters of target angiomyolipomas was 
reduced throughout the trial compared to baseline (Figure 2 and Online Supplementary Table 
1). Of 23 target angiomyolipomas evaluated at 24 months, 21 were smaller and 2 were 
unchanged (Table 1). Of all 48 target angiomyolipomas evaluated during the trial 41 (85%) 
were smaller at the last measurement than at baseline, 2 were unchanged and 5 were larger 
(including 4 from one patient, TSC4, and a 1mm increase in the fifth). (Table 1) 
Angiomyolipomas shrank most quickly early in the trial (Figure 2). For angiomyolipomas 
measured at baseline and at 12 and 24 months there was a mean reduction in longest diameter 
of 7.3mm at 12 months but a further mean reduction of only 0.7 mm at 24 months (Table 1). 
 
Lung Function 
 Lung function in patients with sporadic and tuberous sclerosis-associated 
lymphangioleiomyomatosis showed wide variation at baseline and fell slightly in most patients 
during the trial (Figure 3 and Online Supplementary Table 2). For the 5 patients with 
measurements over 2 years the mean (+/- SD) FEV1 declined by  76 +/-52 ml/yr, mean FVC by 
55 +/-94 ml/yr and mean DLco by -0.49 +/- 0.55 ml/min/mmHg/yr.  
 
 Four patients (LAM1, LAM2, LAM4 and TSC1) had serial measurements of FEV1 
prior to enrollment, for 16, 132, 42 and 106 months respectively. Mean annual change in FEV1 
for these patients before and during the trial were -172 and -94, -122 and -89, -90 and +10 and 
-49 and -69 ml/yr respectively. There were no clinically relevant changes in lung CT 
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appearances during the trial. 
 
Neurocognitive function 
 The mean (+/-SD) IQ of patients with tuberous sclerosis was 107 (+/-12) and of 
sporadic lymphangioleiomyomatosis patients 105 (+/-15). Four patients with tuberous sclerosis 
were taking antiepileptic drugs during the trial but none reported seizures during the trial or in 
the preceding year. Baseline cranial MRI scans in patients with tuberous sclerosis showed 
cortical tubers and sub-ependymal nodules but no subependymal giant cell astrocytomas and 
no changes were seen at 12 months. 
 
Increased recall memory scores were seen in 7 of the 8 tested patients with tuberous sclerosis. 
By contrast, recognition memory scores fell in 5 and none showed an increase. Executive skill 
scores increased in 5 of 8 patients with tuberous sclerosis. Changes in neurocognitive scores 
were also observed in patients with sporadic lymphangioleiomyomatosis (Figure 4 and Online 
Supplementary Table 3). 
 
Adverse events 
 The most common adverse events were oral mucositis (6 of 16 patients), respiratory 
infections (5 patients) and proteinuria (5 patients) (Table 2). Seven serious adverse events 
occurred of which 3 were possibly related to sirolimus. One patient with severe sporadic 
lymphangioleiomyomatosis died following a respiratory infection and two further patients with 
lymphangioleiomyomatosis were hospitalized, one with pharyngitis and one with a chest 
infection. The four remaining serious adverse events were categorized as not related or 
unlikely to be related to sirolimus: a fractured tibia and fibula, chest pain of unknown cause, 
urinary obstruction secondary to an ovarian cyst and musculoskeletal back pain.  
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Discussion 
This trial determined the response of renal angiomyolipomas in patients with tuberous 
sclerosis or sporadic lymphangioleiomyomatosis to 2 years of sirolimus treatment. A tumour 
response by RECIST criteria28 was observed 8 of 16 patients overall and 8 of 10 in the per-
protocol group. Of 23 angiomyolipomas evaluated at 24 months, 21 were smaller and 2 were 
unchanged. Although all target angiomyolipomas shrank in most patients, one (TSC4) who had 
the most target lesions and who withdrew at 12 months, showed heterogeneity of tumour 
response with 5 of 9 angiomyolipomas shrinking and 4 growing. One previous trial reported by 
Bissler et al. investigated sirolimus treatment for angiomyolipomas in patients with tuberous 
sclerosis or sporadic lymphangioleiomyomatosis and found a mean reduction in 
angiomyolipoma volume of 47% at 12 months.19 In the current trial angiomyolipomas 
measured at 12 months showed a mean reduction in their longest diameters of 25% compared 
to baseline, equivalent to a volume reduction of 60% if a spherical shape is assumed. While 12 
of 16 patients in the current trial were maintained at trough blood levels of 3-6 ng/ml and the 
others 4 at 6-10 ng/ml all but one of the patients in the trial by Bissler et al. were escalated to 
trough blood levels of 10-15 ng/ml. The current trial shows that sirolimus levels at the lower 
end of the immunosuppressive range are effective in reducing angiomyolipoma size in 
tuberous sclerosis or sporadic lymphangioleiomyomatosis. 
In the trial reported by Bissler et al. angiomyolipoma volumes increased after sirolimus 
therapy was withdrawn at 12 months, returning from 53% to 85.9% of the baseline value by 24 
months.19 In the current trial the mean longest diameter of angiomyolipomas measured at both 
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12 and 24 months was 2.19cm and 2.11cm respectively, indicating that tumour response was 
maintained by continuation of therapy but little further shrinkage occurred during the second 
year of treatment. Long term sirolimus therapy may be needed to prevent tumour re-growth in 
patients with tuberous sclerosis or lymphangioleiomyomatosis and this could be acceptable, as 
it is in organ transplant recipients. 
In recent studies of lymphangioleiomyomatosis the mean rate of decline in FEV1 has 
ranged from 75-118 ml/yr.31-33 During this trial it was 76 ml/yr in the 5 patients who had 
measurements over 2 years and 49 ml/yr in 7 patients with measurements over one year or more. 
We did not observe a significant improvement in lung function during sirolimus therapy as was 
reported by Bissler et al.19 but neither study was powered to evaluate lung function. A recently 
reported randomised control trial of sirolimus for the treatment of lymphangioleiomyomatosis 
suggests that sirolimus may prevent or reduce decline in lung function, consistent with our 
findings34. 
 
The reversal of spatial learning deficits by rapamycin (sirolimus) treatment in 
heterozygous Tsc2 mice15 has suggested that mTORC1 inhibitors might also improve specific 
neurocognitive problems associated with tuberous sclerosis.35 The non-randomised design and 
small patient numbers restricted the analysis of neurocognitive outcomes in this trial and the 
patients with tuberous sclerosis were mildly affected with far fewer neurocognitive problems 
than more typical patients. Nevertheless, scores for recall memory, that has been associated 
with mTOR activity15, increased in 7 of 8 patients with tuberous sclerosis while those for 
recognition memory did not. Larger randomised control trials are warranted to determine 
whether treatment-related changes in neurocognition occur with mTORC1 inhibition in 
patients with and without tuberous sclerosis. 
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Adverse events were common, consistent with the known toxicities of sirolimus and 
mostly of low grade. However, one patient with severe lymphangioleiomyomatosis died of a 
respiratory infection during this study. Because of their immunosuppressive properties, the risks 
and benefits of mTORC1 inhibitors need specific and careful evaluation in this setting. 
 
Although our trial involved a small number of patients and was non-controlled and 
open label it reports one of the earliest examples of therapeutic targeting of tumours in the 
context of both a mendelian and a sporadic disorder by inhibition of a shared signaling 
pathway. The high response rate seen in the trial underscores the potential for effective targeted 
treatment when the setting is one of relative molecular homogeneity. 
Recruitment to the trial proved difficult, reflecting the rarity of these disorders and our 
restrictive inclusion criteria, particularly for patients with tuberous sclerosis. Nonetheless, it 
provides evidence that renal angiomyolipomas in patients with tuberous sclerosis or sporadic 
lymphangioleiomyomatosis decrease in size in response to treatment with sirolimus and that 
this response is maintained by continuation of treatment for 2 years. Larger trials should now 
address whether, in patients with large tumours and/or extensive renal involvement, mTORC1 
inhibition leads to reduction of the clinically important complications of renal 
angiomyolipoma, notably haemorrhage and renal failure. 
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Figure Legends 
Figure 1. Flow diagram summarising patients and assessments. 
One patient who was still in the study was unable to undergo magnetic resonance imaging of the 
kidneys at the 2-month assessment and another at the 6-month assessment because of inter-
current illness. # One patient was unable to undergo pulmonary function tests at 6 and at 12 
months because of inter-current illness. 
 
Figure 2. Changes in angiomyolipoma burden during sirolimus therapy. 
Renal angiomyolipomas were measured at baseline and at 2,6,12 and 24 months by magnetic 
resonance imaging. The sum of the longest diameters of all target angiomyolipomas in each 
patient was calculated at each time point and the percentage reduction calculated by comparison 
to the baseline value. Each solid line shows change in angiomyolipoma burden in one patient. 
The upper dashed line represents the baseline value and the lower dashed line 70% of the 
baseline value. Patients in whom the sum of the longest diameters of target angiomolipomas fell 
below 70% of the baseline value are defined as partial responders by the RECIST criteria. 
 
 
 
Figure 3. Pulmonary function studies in patients with sporadic or tuberous sclerosis-
associated lymphangioleiomyomatosis. 
 
Forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC) and diffusing 
capacity of the lung for carbon monoxide (DLco) are shown as percentages of the predicted value 
for women of equivalent age and height24.  
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Figure 4.  Changes in Neurocognitive Test Performance in Patients with Tuberous Sclerosis 
(TSC) and Sporadic Lymphangioleiomyomatosis (LAM). 
Neurocognitive test performance at baseline and at 12 months (but at 4 months in patients TSC4 
and LAM6 who withdrew prior to the 12 month assessment) was measured using parallel test 
versions. Test scores were converted to percentile band scores according to published UK norms 
for age and sex for each test version. This enabled comparisons to be made between parallel test 
versions. We calculated summary scores across the tests in each neurocognitive domain30 by 
allocating an integer score to each centile band (below 5th = 1, 5th-9th = 2, 10th-24th = 3, 25th-49th 
= 4, 50th-74th = 5, 75th-89th = 6, 90th and above = 7) and adding the integer scores (given in 
Supplementary Table 3) together. (A) The total immediate recall memory score was the sum of 
the integer scores for list leaning, story recall and figure recall; (B) the total immediate 
recognition memory score was the sum of the pattern recognition and spatial recognition integer 
scores and (C) the total executive score was the sum of the SWM, SOC and IDED integer scores. 
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Tables 
 
Patient Angiomyolipoma  baseline 2 Months 6 Months 12 Months 24 Months 
LAM1 R1 2.2 1.4 ND               2.0 Deceased
 R2 2.6 2.7 ND                2.3 Deceased 
 R3 2.3 2.3 ND                1.9    
LAM2 R1 2.8 2.5 1.4 1.2 1.0 
 R2 2.0 2.0 1.9 1.6 1.4
LAM3 R1 2.2 1.9 1.9 1.9 1.3 
LAM4* L1 2.8 2.5 2.8 2.4 2.2 
 L2 2.0 1.9 1.6 1.3 0.8 
LAM5 R1 2.3 2.2 Withdrew   
LAM6 L1 5.6 3.4 Withdrew  
 L2 2.7 1.7 Withdrew   
 L3 2.6 1.8 Withdrew   
TSC1(LAM) R1 2.4 1.9 1.9 1.9 2.0 
 R2 2.2 1.4 1.4 1.3 1.3 
TSC2(LAM) R1 3.2 2.6 2.1 2.3 Withdrew
 R2 2.2 1.8 1.4 1.6 Withdrew 
 R3 2.2 2.1 2.0 2.0 Withdrew 
 L1 3.8 3.4 2.8 2.4 Withdrew 
TSC3 R1 2.4 2.2 2.1 Withdrew  
 R2 2.4 1.9 1.9 Withdrew  
 L1 5.4 4.6 4.3 Withdrew  
 L2 2.2 2.4 1.9 Withdrew  
 L3 2.7              2.6 2.8 Withdrew  
TSC4 R1 14.1 12.8 13.3 Withdrew 
 R2 2.7 2.7 2.5 Withdrew 
 R3 3.4 3.3 3.7 Withdrew  
 R4 3.2 4.2 4.2 Withdrew  
 R5 5.4 5.4 6.4 Withdrew  
 L1 10.6 10.2 8.3 Withdrew 
 L2 4.4 4.5 4.8 Withdrew  
 L3 3.6 3.5 3.4 Withdrew  
 L4 3.4 3.3 3.2 Withdrew  
TSC5* R1 2.3 1.9 1.8 1.8 1.6 
 R2 4.5 3.8 2.8 2.8 2.9
TSC6 R1 2.4             ND 2.3 1.8 1.6 
 L1 2.8             ND 2.3 1.7 2.1 
 L2 2.4             ND 2.6 1.9 1.9 
TSC7* R1 2.5 2.4 2.2 1.8 1.8 
 R2 3.8 2.8 2.7 2.8 3.2
 R3 3.3 2.4 2.3 2.1 2.1 
 R4 2.9 2.2 2.4 2.1 1.9 
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Patient Angiomyolipoma  baseline 2 Months 6 Months 12 Months 24 Months 
TSC8(LAM) R1 3.9 2.3 2.6 2.5 2.5 
 L1 4.3 3.1 3.6 4.2 4.3 
TSC9* R1 2.0 1.7 1.7 1.9 1.7 
 R2 4.2 3.5 3.8 3.2 3.2 
TSC10 R1 2.9 2.8 2.8 2.2 2.0 
 L1 3.2 2.9 2.7 2.5 2.5 
 L2 3.3 3.5 3.3 3.4 3.3 
  
 
Table 1. Longest Diameters of Individual Target Angiomyolipomas. 
Target angiomyolipomas in the right (R) and/or left (L) kidney in each patient were visualised by 
magnetic resonance imaging (MRI) at baseline and at 2,6,12 and 24 months and the longest 
diameter of each angiomyolipoma was measured. Values are in cm. ND =  MRI not done due to 
inter-current illness. TSC1-TSC10 = patients with tuberous sclerosis. LAM1-LAM6 = patients 
with sporadic lymphangioleiomyomatosis. TSC(LAM) indicates patients with tuberous sclerosis 
and lymphangioleiomyomatosis. * These patients had previous unilateral nephrectomy for 
angiomyolipoma. 
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Category Diagnosis No. of 
Events 
No. of  
patients 
Grade 
1-2 
Grade 
3-4 
Grade 
5 
       
GASTROINTESTINAL       
Oral mucositis All 9 6 9 - - 
 SLAM 4 3 4 - - 
 TLAM 3 2 3 - - 
 TSC 2 1 2 - - 
Diarrhoea All 1 1 1 - - 
   SLAM 1 1 1 - - 
 TLAM - - - - - 
 TSC - - - - - 
Nausea All 1 1 1 - - 
 SLAM 1 1 1 - - 
 TLAM - - - - - 
 TSC - - - -  
INFECTION       
Upper respiratory tract or bronchitis All 16 5 14 1 1 
   SLAM 16 5 14 1* 1* 
 TLAM - - - - - 
 TSC - - - - - 
Pharyngitis All 1 1 - 1 - 
   SLAM 1 1 - 1* - 
 TLAM - - - - - 
 TSC - - - - - 
Urinary tract infection All 3 3 3 - - 
   SLAM 2 2 2 - - 
 TLAM 1 1 1 - - 
 TSC - - - - - 
Cellulitis All 2 2 2   
   SLAM - - - - - 
 TLAM 1 1 1 - - 
 TSC 1 1 1 - - 
Oral cavity All 1 1 1 - - 
 SLAM 1 1 1 - - 
 TLAM - - - - - 
 TSC - - - - - 
METABOLIC       
Proteinuria All 5 5 5 - - 
 SLAM    - - 
 TLAM 1 1 1 - - 
 TSC 4 4 4 - - 
Raised creatine kinase All 3 3 3 - - 
   SLAM    - - 
 TLAM 2 2 2 - - 
 TSC 1 1 1 - - 
Hypertriglyceridaemia All 2 2 2 - - 
 SLAM - - - - - 
 TLAM 1 1 1 - - 
 TSC 1 1 1 - - 
Raised ALP All 1 1 1 - - 
 SLAM - - - - - 
 TLAM - - - - - 
 TSC 1 1 1 - - 
Hypokalaemia All 1 1 1 - - 
 SLAM 1 1 1 - - 
 TLAM - - - - - 
 TSC - - - - - 
SOFT TISSUES       
Peripheral oedema All 3 3 3 - - 
 SLAM - - - - - 
 TLAM 1 1 1 - - 
 TSC 2 2 2 - - 
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Category Diagnosis No. of 
events 
No. of  
patients 
Grade 
1-2 
Grade 
3-4 
Grade 
5 
CONSTITUTIONAL SYMPTOMS       
General malaise All 1 1 1 - - 
 SLAM 1 1 1 - - 
 TLAM - - - - - 
 TSC - - - - - 
Fatigue All 3 3 3 - - 
 SLAM - - - - - 
 TLAM 2 2 2 - - 
 TSC 1 1 1 - - 
DERMATOLOGY       
Acneform rash All 2 2 2 - - 
   SLAM - - - - - 
 TLAM - - - - - 
 TSC 2 2 2 - - 
Exacerbation of eczema All 1 1 1 - - 
 SLAM - - - - - 
 TLAM 1 1 1 - - 
 TSC - - - - - 
CARDIAC       
Palpitations All 2 2 2 - - 
 SLAM 2 2 2 - - 
 TLAM - - - - - 
 TSC - - - - - 
NEUROLOGY       
Depression All 1 1 1 - - 
 SLAM - - - - - 
 TLAM - - - - - 
 TSC 1 1 1 - - 
ENDOCRINE       
Hypothyroidism All 1 1 1 - - 
 SLAM - - - - - 
 TLAM - - - - - 
 TSC 1 1 1 - - 
OCULAR       
Retinal tear All 1 1 1 - - 
 SLAM - - - - - 
 TLAM 1 1 1 - - 
 TSC - - - - - 
BLOOD       
Anaemia All 1 1 1 - - 
 SLAM - - - - - 
 TLAM - - - - - 
 TSC 1 1 1 - - 
 
 
Table 2. Sirolimus-Related Adverse Reactions. 
Sirolimus related adverse reactions were those adverse events that were considered to be 
possibly, probably or definitely related to sirolimus. *These events were reported as severe 
adverse events, defined as those that resulted in death or were life-threatening, required 
hospitalization or resulted in disability. “All”, All patients N = 16; “SLAM”, Sporadic 
lymphangioleiomyomatosis N = 6; “TLAM”, tuberous sclerosis with lymphangioleiomyomatosis 
N = 3; “TSC”, tuberous sclerosis only N =  7. 
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Online-Only Material: Supplementary online materials are Tables 1-3. 
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14 had neurocognitive  
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